 |
|
|
| |
Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world
population of Genotype 3 HCV; data from the TRIO network
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Kris Kowdley1, Bruce Bacon2, Douglas T. Dieterich3, Eric Lawitz 4, Scott Milligan5, Naoky Tsai6, Zobair Younossi7, Steven L. Flamm8
1Liver Care Network, Swedish Medical Center, Seattle, WA, 2Saint Louis University School of Medicine, 3Icahn School of Medicine at Mount Sinai, 4The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, 5Trio Health Analytics, 6Queens Medical Center, University of Hawaii, 7Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 8Northwestern University Feinberg School of Medicine
|
| |
|
|
|
|
|
